BACKGROUND
Familial combined hypolipidemia, a Mendelian condition characterized
by substantial reductions in all 3 major lipid fractions, is caused by
mutations that inactivate the gene angiopoietin-like 3
(ANGPTL3). Whether ANGPTL3 deficiency reduces risk of
coronary artery disease (CAD) is unknown.
OBJECTIVES
The study goal was to leverage 3 distinct lines of evidence –
a family that included individuals with complete (compound heterozygote)
ANGPTL3 deficiency, a population based-study of humans with partial
(heterozygote) ANGPTL3 deficiency, and biomarker levels in myocardial
infarction (MI) patients – to test if ANGPTL3 deficiency is
associated with lower risk for CAD.
METHODS
We assessed coronary atherosclerotic burden in 3 individuals with
complete ANGPTL3 deficiency and 3 wild-type first-degree relatives using
computed tomography angiography. In the population, ANGPTL3
loss-of-function (LOF) mutations were ascertained in up to 21,980
individuals with CAD and 158,200 controls. LOF mutations were defined as
nonsense, frameshift, and splice-site variants, along with missense variants
resulting in <25% of wild-type ANGPTL3 activity in a mouse model.
In a biomarker study, circulating ANGPTL3 concentration was measured in
1,493 individuals presenting with MI and 3,232 controls.
RESULTS
The 3 individuals with complete ANGPTL3 deficiency showed no evidence
of coronary atherosclerotic plaque. ANGPTL3 gene sequencing
demonstrated that approximately 1 in 309 individuals was a heterozygous
carrier for an LOF mutation. Compared to those without mutation,
heterozygous carriers of ANGPTL3 LOF mutations demonstrated
a 17% reduction in circulating triglycerides and a 12%
reduction in low-density lipoprotein cholesterol. Carrier status was
associated with a 34% reduction in odds of CAD (odds ratio: 0.66;
95% confidence interval: 0.44 to 0.98; p = 0.04).
Individuals in the lowest tertile of circulating ANGPTL3 concentrations,
compared with the highest, had reduced odds of MI (adjusted odds ratio:
0.65; 95% confidence interval: 0.55 to 0.77; p < 0.001).
CONCLUSIONS
ANGPTL3 deficiency is associated with protection from CAD.
Genotyping arrays are a cost effective approach when typing previously-identified genetic polymorphisms in large numbers of samples. One limitation of genotyping arrays with rare variants (e.g., minor allele frequency [MAF] <0.01) is the difficulty that automated clustering algorithms have to accurately detect and assign genotype calls. Combining intensity data from large numbers of samples may increase the ability to accurately call the genotypes of rare variants. Approximately 62,000 ethnically diverse samples from eleven Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium cohorts were genotyped with the Illumina HumanExome BeadChip across seven genotyping centers. The raw data files for the samples were assembled into a single project for joint calling. To assess the quality of the joint calling, concordance of genotypes in a subset of individuals having both exome chip and exome sequence data was analyzed. After exclusion of low performing SNPs on the exome chip and non-overlap of SNPs derived from sequence data, genotypes of 185,119 variants (11,356 were monomorphic) were compared in 530 individuals that had whole exome sequence data. A total of 98,113,070 pairs of genotypes were tested and 99.77% were concordant, 0.14% had missing data, and 0.09% were discordant. We report that joint calling allows the ability to accurately genotype rare variation using array technology when large sample sizes are available and best practices are followed. The cluster file from this experiment is available at www.chargeconsortium.com/main/exomechip.
Excessive alcohol consumption is a major public health problem worldwide. Although drinking habits are known to be inherited, few genes have been identified that are robustly linked to alcohol drinking. We conducted a genome-wide association metaanalysis and replication study among >105,000 individuals of European ancestry and identified β-Klotho (KLB) as a locus associated with alcohol consumption (rs11940694; P = 9.2 × 10
−12). β-Klotho is an obligate coreceptor for the hormone FGF21, which is secreted from the liver and implicated in macronutrient preference in humans. We show that brain-specific β-Klotho KO mice have an increased alcohol preference and that FGF21 inhibits alcohol drinking by acting on the brain. These data suggest that a liver-brain endocrine axis may play an important role in the regulation of alcohol drinking behavior and provide a unique pharmacologic target for reducing alcohol consumption.
Improved understanding of the proteome can facilitate the identification of causal mechanisms for complex traits. We conducted a comprehensive analysis of the common variant cis-regulatory genetic architecture of 4,665 plasma proteins from 7,213 European Americans (EA) and 1,871 African Americans (AA) from the Atherosclerosis Risk in Communities (ARIC) cohort study. We identified and fine-mapped 1,992 plasma proteins in EA and 1,605 in AA, which had significant cis-single-nucleotide polymorphism (SNP) associations. Estimates of cis-heritability (cis-h 2 ) for plasma proteins were similar across EA and AA (median cis-h 2 =0.09 for EA and 0.10 for AA).Elastic-net-based models for cis-SNP-based protein prediction produced high accuracy (median R 2 /cis-h 2 =0.79 for EA and 0.69 for AA). We illustrate the application of these models to conduct proteome-wide association studies (PWAS) for two related complex traits, serum urate and gout, and further conduct conditional analyses to interpret findings in the context of those from transcriptome-wide association studies (TWAS).
Excessive alcohol consumption is one of the main causes of death and disability worldwide. Alcohol consumption is a heritable complex trait. We conducted a meta-analysis of genome-wide association studies (GWAS) of gram/day (g/d) alcohol consumption in UK-Biobank, AlcGen and CHARGE+ consortia accumulating 480,842 people of European descent to decipher the genetic architecture of alcohol intake. We identified 46 novel, common loci, and investigated their potential functional significance using magnetic resonance imaging data and gene expression studies. Our results identify genetic pathways associated with alcohol consumption and suggest shared genetic mechanisms with neuropsychiatric disorders including schizophrenia.
Genetic studies of blood pressure (BP) to date have mainly analyzed common variants (minor allele frequency, MAF > 0.05). In a meta-analysis of up to >1.3 million participants, we discovered 106 new BP-associated genomic regions and 87 rare (MAF ≤ 0.01) variant BP associations (
P
< 5 × 10
-8
), of which 32 were in new BP-associated loci and 55 were independent BP-associated SNVs within known BP-associated regions. Average effects of rare variants (44% coding) were ~8 times larger than common variant effects and indicate potential candidate causal genes at new and known loci (
e.g. GATA5
,
PLCB3
). BP-associated variants (including rare and common) were enriched in regions of active chromatin in fetal tissues, potentially linking fetal development with BP regulation in later life. Multivariable Mendelian randomization suggested possible inverse effects of elevated systolic and diastolic BP on large artery stroke. Our study demonstrates the utility of rare variant analyses for identifying candidate genes and the results highlight potential therapeutic targets.
RLP-C and LDL-TG levels were predictive of CVD and associated with APOE variants. LDL-TG may represent a marker of dysfunctional remnant lipoprotein metabolism associated with increased CVD risk. Further research is needed to determine whether LDL-TG plays a causal role in CVD and may be a target for therapy.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.